ADRB2 |
Adrenergic receptor, beta 2 |
0.462 |
(0.40, 0.53) |
0.00001 |
|
|
|
|
|
|
AREG |
Amphiregulin |
0.476 |
(0.41, 0.54) |
< 0.00001 |
|
|
|
|
|
|
CCL5 |
Chemokine (C-C motif) ligand 5 |
0.226 |
(0.10, 0.36) |
0.00119 |
|
|
|
|
|
|
CLCA1 |
Chloride channel accessory 1 |
0.129 |
(0.03, 0.23) |
0.02891 |
0.162 |
(0.06, 0.26) |
0.03048 |
|
|
|
CMA1 |
Chymase 1, mast cell |
0.068 |
(0.04, 0.10) |
0.00037 |
0.353 |
(0.20, 0.50) |
0.00421 |
|
|
|
EPX |
Eosinophil peroxidase |
0.037 |
(0.03, 0.04) |
< 0.00001 |
0.213 |
(0.11, 0.31) |
< 0.00001 |
|
|
|
FOXP3 |
Forkhead box P3 |
0.257 |
(0.12, 0.40) |
0.00038 |
|
|
|
|
|
|
IL3RA |
Interleukin 3 receptor, alpha (low affinity) |
|
|
|
0.344 |
(0.16, 0.52) |
0.00364 |
|
|
|
IL4R |
Interleukin 4 receptor |
0.261 |
(0.24, 0.28) |
< 0.00001 |
|
|
|
|
|
|
IL5 |
Interleukin 5 (colony-stimulating factor, eosinophil) |
0.319 |
(0.06, 0.58) |
0.01014 |
|
|
|
|
|
|
IL13RA1 |
Interleukin 13 receptor, alpha 1 |
0.343 |
(0.29, 0.40) |
< 0.00001 |
|
|
|
|
|
|
IL33 |
Interleukin 33 |
0.185 |
(0.16, 0.21) |
< 0.00001 |
|
|
|
|
|
|
LTB4R |
Leukotriene B4 receptor |
0.194 |
(0.16, 0.23) |
< 0.00001 |
0.451 |
(0.39, 0.52) |
0.00001 |
|
|
|
MAF |
V-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) |
0.237 |
(0.20, 0.28) |
< 0.00001 |
0.330 |
(0.29, 0.37) |
0.00001 |
|
|
|
MMP9 |
Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) |
0.274 |
(0.22, 0.33) |
0.00001 |
|
|
|
|
|
|
PMCH |
Pro-melanin-concentrating hormone |
0.271 |
(0.17, 0.37) |
0.00188 |
0.087 |
(0.03, 0.14) |
0.00047 |
|
|
|
POSTN |
Periostin, osteoblast specific factor |
0.176 |
(0.16, 0.19) |
< 0.00001 |
|
|
|
|
|
|
RORC |
RAR-related orphan receptor C |
0.180 |
(0.00001, 0.36) |
0.02731 |
|
|
|
|
|
|
SATB1 |
SATB homeobox 1 |
0.481 |
(0.31, 0.65) |
0.00148 |
|
|
|
|
|
|
STAT5A |
Signal transducer and activator of transcription 5A |
0.328 |
(0.27, 0.38) |
0.00001 |
|
|
|
|
|
|
TNFSF4 |
Tumor necrosis factor (ligand) superfamily, member 4 |
0.197 |
(0.08, 0.31) |
< 0.00001 |
|
|
|
|
|
|